Dermata Therapeutics (Dermata Therapeutics) Stock Based Compensation : $0.98 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Dermata Therapeutics Stock Based Compensation?

Dermata Therapeutics's Stock Based Compensation for the three months ended in Mar. 2024 was $0.59 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 was $0.98 Mil.

Dermata Therapeutics Stock Based Compensation Historical Data

The historical data trend for Dermata Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermata Therapeutics Stock Based Compensation Chart

Dermata Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Stock Based Compensation

1.91

0.93

0.52

Dermata Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Stock Based Compensation	Get a 7-Day Free Trial													0.13	0.13	0.13	0.13	0.59

Dermata Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.98 Mil.

Dermata Therapeutics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Dermata Therapeutics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Dermata Therapeutics (Dermata Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermata Therapeutics Inc (NAS:DRMAW) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

DRMA:USA

Address

3525 Del Mar Heights Road, Suite No. 322, San Diego, CA, USA, 92130

Website

https://www.dermatarx.com

Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.